

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105886 A2

(51) International Patent Classification⁷: **A61K 38/17, G01N 33/68, A61P 9/10 // C07K 14/705**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: **PCT/SE03/01012**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 16 June 2003 (16.06.2003)

English

(25) Filing Language:

English

(26) Publication Language:

(30) Priority Data:

0201844-8 17 June 2002 (17.06.2002) SE
60/388,747 17 June 2002 (17.06.2002) US

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*):
CARTELA AB [SE/SE]; Biomedical Center, I 12, SE-221 84 Lund (SE).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LUNDGREN-ÅKER-LUND, Evy [SE/SE]; Trollsjövägen 165, S-237 33 Bjärred (SE).**

(74) Agents: **ALBIHNS Malmö AB et al.; P.O. Box 4289, S-203 14 Malmö (SE).**

BEST AVAILABLE COPY

WO 03/105886 A2

(54) Title: METHODS AND USES OF THE INTEGRIN ALPHA 10 CHAIN, FOR PREVENTING PROGRESSION OF ATHEROSCLEROSIS PLAQUE FORMATION

(57) Abstract: An antigen indicative of the presence of atherosclerotic plaque is provided. The antigen is used in a method for slowing or arresting progression and/or effecting regression of atherosclerotic plaque in a mammal, comprising administering to the mammal a binding agent having binding sites specific for said antigen of said mammal. Also included are methods for diagnosing a mammal who has a risk of developing atherosclerosis, comprising determining the amount of said antigen. Moreover, uses of said antigen for detection and diagnosing atherosclerosis is provided.

Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation

TECHNICAL FIELD

This invention relates to methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation in a mammal. Also included is a method and use of the integrin alpha 10 chain for detecting atherosclerotic plaque in a mammal.

BACKGROUND OF THE INVENTION

10

Atherosclerosis

Atherosclerosis and its thrombotic complications are the major cause of morbidity and mortality in industrialised countries. The number of prevalent atherosclerotic cases in 2000 totalled nearly 174 million in the major pharmaceutical markets and this figure will continue to increase with the increase in the ageing population. Still, only a fraction of these show overt signs of the disease. The rest remain undiagnosed until the disease manifests itself symptomatically, in the worst case as a heart attack or stroke.

Atherosclerosis is a focal pathological phenomenon characterised by the thickening and hardening of arteries due to the accumulation of lipids (mainly cholesterol esters), carbohydrates, blood products, fibrous tissue and calcium within the vessel wall beginning with the subendothelial space. The gradual build-up of fatty deposits leads to the formation of plaques, which eventually narrow and block the artery. The causes and detection of such plaque formation has been intensely investigated.

Atherosclerosis can occur in any artery. In coronary arteries, it may result in heart attacks; in cerebral arteries it may result in strokes; in peripheral arteries it may result in gangrene of the extremities.

The American Heart Association Committee on Vascular Lesions (Stary *et al*, Arterioscler Thromb. Vasc. Biol., 1995;15(9):1512-31) has developed a standardised classification of distinct plaques simplified by Fuster (Fuster *et al*, Circulation, 1994 Oct;90(4):2126-46) and reviewed by Corti *et al* (Ann N Y Acad Sci. 2001;947:181-95; and discussion on pages 195-8).

35 *The process of atherosclerosis*

The process of atherosclerosis can be viewed as a special type of chronic inflammation where monocytes adhere to the vessel wall and accumulate in the intima. In the presence of low-density lipoproteins (LDL) the monocytes are converted to activated macrophages, which take up lipoprotein particles and become

foam cells. This is followed by migration and proliferation of vSMCs (vascular smooth muscle cells) within the arterial intima, leading to the great intimal expansion seen in atherosclerotic plaques.

The proliferation of the vSMCs is concomitant with a phenotypic modulation

5 of the vSMCs from a contractile to a synthetic phenotype. In addition to proliferation, this phenotypic modulation leads to an increase in the production of extracellular matrix (ECM) molecules (Thyberg et al, Arteriosclerosis.

1990;10(6):966-90). The ECM is critical for the maintenance of vascular integrity and imparts tensile strength, viscoelasticity, elastic recoil and compressibility

10 through the distinct properties of its constituents. Interactions between the ECM and vSMCs are mediated via cell surface receptors such as integrins. Integrins are heterodimeric molecules consisting of non-covalently bound alpha and beta subunits. These molecules mediate a broad distribution of interactions between cells and extracellular matrix components and affect a number of cellular responses 15 including adhesion, migration, proliferation, differentiation, and apoptosis.

Alpha10

A newly discovered collagen-binding integrin, alpha10beta1, includes the integrin subunit alpha10 (Camper et al., (1998) J. Biol. Chem. 273:20383-20389).

20 The integrin is expressed on chondrocytes and shows a M_r of 160 kDa after reduction when isolated from bovine chondrocytes by collagen type II affinity purification.

Cloning and cDNA sequencing showed that it shares the general structure of other integrin alpha subunits. The predicted amino acid sequence consists of a 1167-amino acid mature protein, including a signal peptide (22 amino acids), a long 25 extracellular domain (1098 amino acids) a transmembrane domain (22 amino acids), and a short cytoplasmic domain (22 amino acids). In contrast to most alpha-integrin subunits, the cytoplasmic domain of alpha10 does not contain the conserved sequence KXGFF(R/K)R. Instead, the predicted amino acid sequence in alpha10 is 30 KLGFFAH. It is suggested that the GFFKR motif in alpha-chains are important for association of integrin subunits and for transport of the integrin to the plasma membrane (De Melker et al. (1997) Biochem. J. 328:529-537).

The extracellular part contains a 7-fold repeated sequence, an I-domain (199 amino acids) and three putative divalent cation-a binding site. Sequence analysis has 35 revealed that the alpha10 subunit is most closely related to the I domain-containing α subunits with the highest identity to alpha1 (37%), alpha2 (35%) and alpha11 (42%).

The role of integrins in atherosclerosis

Although several integrins are known to be present on normal vSMCs (Raines E.W., Int J Exp Pathol. 2000;81(3):173-82), little is known about the changes in integrin expression during atherosclerosis. It has been shown that injured 5 synthetic vSMCs, in atherosclerosis, are able to modulate their integrin expression by switching from alpha1beta1 to alpha2beta1 and increase their production of fibrillar collagens, particularly collagen I (Skinner et al, Am J Pathol. 1994;145(5):1070-81.; Thyberg et al, Arteriosclerosis, 1990;10(6):966-90).

Cellular interactions are critical for the development of the atherosclerotic 10 lesion at all stages of its evolution. The integrins, which are receptors for ECM-molecules such as collagens, have critical roles in the vSMCs communication with the extracellular matrix and modulating the phenotype of the vSMCs (Hynes R.O., Cell. 1992;69(1):11-25). Future therapy will be directed towards the modulation of 15 these adhesive interactions mediated by the integrins, which in turn may arrest the development of the atherosclerotic plaque, limit plaque activation and attenuate the thrombotic response accompanying activation.

To-date, treatment of atherosclerosis is mainly performed by dietary 20 adjustments and administration of cholesterol-lowering drugs to slow down or even halter the development of atherosclerosis. However, only limited success has been reported for regression of atherosclerosis. i.e. diminution of the atherosclerotic fatty 25 plaque deposits.

It is thus highly desirable in the light of the aforementioned problems to develop means and methods for suitable therapeutic target molecules and potential 25 diagnostic markers in atherosclerosis, and especially for the inhibition and regression of atherosclerotic plaques. In this respect, the present invention addresses this need and interest.

SUMMARY OF THE INVENTION

In view of the foregoing disadvantages known in the art when treating a 30 mammal for atherosclerosis, or detecting atherosclerotic plaque, the present invention provides an antigen indicative of the presence of atherosclerotic plaque, namely the integrin alpha10 chain, suitable for preventing, treating or detecting atherosclerosis.

One object with the present invention is to provide methods for slowing or 35 arresting progression and/or affecting regression of atherosclerotic plaque in a mammal.

Another object is to provide a method for detecting atherosclerotic plaque in a mammal.

Thus, the present invention provides a method for slowing or arresting the

progression and/or effecting regression of atherosclerotic plaque in a mammal. The method comprises the steps of

- a) administering to the mammal an effective amount of a binding agent having a binding site specific for integrin alpha10 chain or the nucleic acid encoding said chain on the cell surface or intracellular of said mammal,
- b) scoring the progression and/or regression of atherosclerotic plaque, and
- c) correlating the scoring in b) above to slowing or arresting the progression and/or effecting the regression of atherosclerotic plaque.

Also, the present invention provides a method for treating atherosclerosis in mammals in the need thereof, the method comprising the step of administering to the mammal an effective amount of a binding agent having a binding site specific for integrin alpha10 chain on the cell surface or intracellular of said mammal.

Further, the present invention provides a method for diagnosing a mammal who has or may be at risk of developing atherosclerosis, the method comprising the steps of

- a) determining the amount of integrin alpha10 chain in a mammal.
- b) scoring the amount of integrin alpha10 chain in said mammal, relative to a control,
- c) correlating the amount obtained in step b) above with amounts obtained from the control to determine whether the mammal has or is at risk of developing atherosclerosis.

Further embodiments include wherein the determining is performed in vivo. Further embodiments include wherein the determining is performed in vitro.

The method according to the invention may in further embodiments include wherein determining of the amount of integrin alpha10 chain further comprises contacting the sample with a binding agent having a binding site specific for said of integrin alpha10 chain.

Even further, the present invention include a method for detecting atherosclerotic plaque in a mammal, the method comprising the steps of

- a) determining the amount of integrin alpha10 chain in a mammal.
- b) scoring the amount of integrin alpha10 chain in said mammal, relative to a control, and
- c) correlating the amount obtained in step b) above with amounts obtained from the control to detect said atherosclerotic plaque in the mammal.

The methods according to the invention may in further embodiments include wherein the mammal is a human, or a rodent, such as a rabbit, mouse or rat, or a primate, such as chimpanzees, squirrel monkeys, howler monkeys, rhesus monkeys and cynomolgus monkeys, or a pig, e.g. the White Belgian pig.

Further embodiments include wherein the mammal is fed a high-cholesterol

and/or high-fat diet.

Uses of the integrin alpha10 chain for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque, for the preparation of a composition for the treatment of atherosclerosis, for diagnosing atherosclerosis and 5 for detecting atherosclerotic plaque are also provided.

SHORT DESCRIPTION OF DRAWINGS

Fig. 1 shows phases and lesion morphology in the progression of atherosclerosis (from: Corti et al 2001 Ann. N.Y Acad. Sci 947:181-198), and

10 Fig. 2 shows the detection of integrin alpha10 chain in an atherosclerotic plaque of a murine aorta. The top picture, A, shows the staining of the integrin alpha10 chain as a strong staining of the cell surface of a cell in the aortic plaque. The middle photo, B, shows a specific blocking of the integrin alpha10 chain staining with a peptide of the integrin alpha10 chain, wherein almost all staining has 15 been blocked by the peptide. The bottom photo, C, shows a control staining using secondary antibody only. No unspecific binding due to the secondary antibody, a donkey-anti-rabbit Cy3, is detected.

DETAILED DESCRIPTION OF THE INVENTION

20 Definitions

As used herein, the term "atherosclerotic plaque" refers to the build up of fatty plaque deposits within the wall of blood vessels.

The terms "rodent" and "rodents" refer to all members of the phylogenetic order *Rodentia*.

25 The term "murine" refers to any and all members of the family *Muridae*, including rats and mice.

A "therapeutically effective amount", or "effective amount", or "therapeutically effective", as used herein, refers to that amount which provides a therapeutic effect for a given condition and administration regimen. This is a 30 predetermined quantity of active material calculated to produce a desired therapeutic effect in association with the required additive and diluent; i.e., a carrier, or administration vehicle. Further, it is intended to mean an amount sufficient to reduce and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is 35 sufficient to cause an improvement in a clinically significant condition in a host. As is appreciated by those skilled in the art, the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or additive.

As used herein, "treating", means treating for curing which may be a full curing or a partial curing of a condition or conditions associated with atherosclerosis.

As used herein "alleviation", means a decreased, i.e. less, or milder condition
5 or conditions associated with atherosclerosis.

As used herein "preventing", means a complete or partial block of development, or outbreak, of a certain condition or conditions associated with atherosclerosis.

In the methods and use of the invention, a therapeutically effective amount of
10 the active component or binding agent is provided. A therapeutically effective amount can be determined by the ordinary skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex, condition, complications, other diseases, etc., as is well known in the art.

15 *The antigen*

As revealed above, the present invention provides an antigen indicative of the presence of atherosclerotic plaque, namely the integrin alpha10 chain sequence. The integrin alpha10 chain is known and publicly available at GenBankTM/EBI Data Bank accession number AF074015. Thus, new uses and methods of said integrin
20 alpha10 chain are disclosed in the present invention.

Accordingly, the present invention provides the use of the integrin alpha10 chain as a therapeutic target molecule and potential diagnostic marker in atherosclerosis to meet today's unmet need for methods that can be used in prevention, early detection and therapy of atherosclerosis.

25

A method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque

According to the invention, a method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque in a mammal is disclosed. Such
30 a method comprises the steps of

- a) administering to the mammal an effective amount of a binding agent having a binding site specific for integrin alpha10 chain on the cell surface of said mammal,
- b) scoring the progression and/or regression of atherosclerotic plaque, and
- 35 c) correlating the scoring in b) above to slowing or arresting the progression and/or effecting the regression of said atherosclerotic plaque.

The administration of an effective amount of a binding agent having a binding site specific for integrin alpha10 chain has to be evaluated in each case. The binding agent is any agent targeting integrin alpha10, such as human integrin

alpha10. The binding agent has to be administered over a range of doses to the mammal in the need thereof, followed by assaying at various time points for (an) effect(s) of the agent on the atherosclerotic plaque. The effective dose of the binding agent can differ from mammal to mammal, and from patient to patient but in general 5 includes amounts starting where clinical or pathological effects or other desired therapeutic effects on the atherosclerotic plaque occur, but below that amount where significant undesirable side effects are observed. The dosage administered will depend on the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of the treatment, and the nature of the effect desired. The effective 10 dosage can be modified by comparing the relative to in vivo potencies of the drugs and the bioavailability using no more than routine experimentation.

The binding agent is generally administered locally and/or systemically together with a pharmaceutically acceptable carrier, diluents and/or other additives. Pharmaceutically acceptable carriers and/or diluents include any and all solvents, 15 dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional medium or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active 20 ingredients can also be incorporated into the compositions.

The binding agent in an effective amount may be administered in any convenient manner, either orally or parenterally such as by intravenous, intra-peritoneal, subcutaneous, rectal, implant, transdermal, slow release, intrabuccal, 25 intracerebral or intranasal administration. For intracerebral administration, the binding agent needs to pass the blood brain barrier and may have to be chemically modified, e.g. made hydrophobic, to facilitate this or be administered directly to the brain or via other suitable routes.

For injectable use, sterile aqueous solutions, where water soluble, are generally used or alternatively sterile powders for the extemporaneous preparation 30 of sterile injectable solutions may be used. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol, for example, glycerol, propylene glycol and liquid 35 polyethylene glycol, and the like, suitable mixtures thereof, and vegetable oils. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the

injectable binding agent can be brought about by the use in the binding agent of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the binding agent in the required amount in the appropriate solvent with various amounts of the other 5 ingredients enumerated above, as required, followed by sterilization by, for example, filtration or irradiation. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique, which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

10 When the binding agents are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with 15 excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The amount of active binding agent is such that a suitable effective dosage will be obtained.

Different forms of tablets, troches, pills, capsules and the like may also be used and contain other components as listed below.

20 The binding agent may in further embodiments be administered together with other agents, such as drugs, proteins, i.e. antibodies and enzymes, or peptides, i.e. polypeptides or oligopeptides, known to effect atherosclerosis, and particularly the atherosclerotic plaques. Such an additional other agent may be administered directly or indirectly linked to the binding agent or non-linked.

25 The binding agent according to the invention may be any protein, such as a monoclonal or polyclonal antibody, or parts thereof; a polypeptide or an oligopeptide binding to the integrin alpha10 chain, or a part thereof, such as the I-domain or the splice domain. The integrin alpha10 chain may also be in a heterodimer formed with the integrin beta1 chain. Thus, the binding agent may bind to both of 30 the integrin chains, i.e. the alpha10beta1 heterodimer.

In further embodiments, the binding agent may bind any intracellular or extra cellular part of the integrin alpha10 chain.

The binding agent may in further embodiments bind to the I-domain and/or the splice domain of the integrin alpha10 chain.

35 The binding agent may also be any other molecule binding to integrin alpha10 chain, or said heterodimer, such as a molecule obtained from screening a chemical library.

In further embodiments, the binding agent may bind to or hybridise any nucleic acid, such as ribonucleic acid, RNA, or deoxyribonucleic acid, DNA, encoding the integrin alpha10 chain.

5 In further embodiments, the binding agent may bind to or hybridise any nucleic acid, such as ribonucleic acid, RNA, or deoxyribonucleic acid, DNA, encoding a protein regulating the expression of the integrin alpha10 chain.

Thus, the binding agent may be any isolated nucleic acid, e.g. a poly-nucleotide or oligonucleotide, such as ribonucleic acid (RNA) deoxyribonucleic acid (DNA), peptide nucleic acid (PNA), which hybridises to said DNA or RNA 10 encoding an integrin subunit alpha10 and wherein said polyoligonucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding other integrins, such as the integrin subunit alpha11, alpha1, alpha2 e.t.c. This is a direct regulation of the alpha10 expression.

15 In further embodiments, the binding agent maybe only other molecule, such as any protein, polypeptide or chemical compound screened from a chemical library regulating the expression of the integrin alpha10 chain directly or indirectly.

Further embodiments include wherein the binding agent is any isolated nucleic acid, e.g. a polynucleotide or oligonucleotide, such as ribonucleic acid (RNA) deoxyribonucleic acid (DNA), peptide nucleic acid (PNA), which hybridises 20 to any nucleic acid, such as ribonucleic acid, RNA, or deoxyribonucleic acid, DNA, encoding a protein regulating the expression of the integrin alpha10 chain. This is an indirect regulation of the alpha10 expression.

Atherosclerotic plaques are build-up in the intima of the arterial wall which comprising an endothelial monolayer on the luminal face with a subcellular elastic 25 extracellular matrix containing a few smooth muscle cells. The fist sign of an atherosclerotic plaque is accumulation of lipoprotein in the intima. The lipoproteins attract monocytes which becomes macrophages that engulfs the lipoproteins (macrophage foam cells). This is followed by a migration and proliferation of smooth muscle cells into the intma, leading to a great thickening of the intima. This 30 is also accompanied by a phenotypic modulation of the smooth muscle cells.

Furthermore, lymphocytes can be seen in the plaques. The smooth muscle cells build-up an extracellular matrix cap that surrounds the lipids and inflammatory cells which is critical for the maintenance of vascular integrity. The plaque becomes a place for chronic inflammation that leads to fibrosis and further thickening of the 35 intima (Stary HC *et al.* Circulation 1995; 92:1355-1374, Fayad ZA *et al.* Circ Res 2001; 98:305-316). The activated macrophages release several matrix degrading metalloproteases which leads to a degradation and instability of the extracellular cap of the plaque. When there is an unbalance between production and degradation of the extracellular matix and the degradation takes overhand there is an increased risk

for plaque rupture. The integrin alpha10 chain has both an intracellular and an extracellular domain on the cells in the atherosclerotic plaques, such as smooth muscle cells, macrophages or endothelial cells.

Thus, further embodiments of the method according to the invention includes
5 wherein the cell is a smooth muscle cell and the binding site on the integrin alpha10 chain is intracellular in and/or extracellular on the surface of such a cell. Functional modulations and numerical increases in intimal smooth muscle cells stand out among cellular changes in advanced human lesions. The smooth muscle cells are in part resident intimal cells that preceded the lesions and in part their progeny that
10 arose as a response to various stimuli. The stimuli include lipid accumulation, disruption of intimal structure, damage to intimal cells and matrix, and deposits of platelets and fibrinogen, all of which may activate resident cells to produce mitogenic factors. Furthermore, the increase in collagen in the atherosclerotic lesions is produced by intimal smooth muscle cells (Stary HC *et al.* Circulation
15 1995; 92:1355-1374).

In a specific embodiment, the binding site specific on the integrin alpha10 chain is on the cell surface of a smooth muscle cell.

The primary *in vivo* effect in a mammal is where the binding agent finds and localises the target, i.e. integrin alpha10 chain, on the cell surface of said cells in the
20 atherosclerotic plaque. Still, for detecting an atherosclerotic plaque *in vitro* or *in vivo*, as described below, the intracellular expression of integrin alpha10 chain may be used as well.

A method for treating atherosclerosis in a mammal in the need thereof

25 According to the invention, a method for treating atherosclerosis in a mammal in the need thereof is disclosed. The method comprises the step of

- a) administering to the mammal an effective amount of a binding agent having a binding site specific for integrin alpha10 chain on the cell surface or intracellular of said mammal.

30 Different embodiments including administration to the mammal, the binding agent as well as cells of interest are further described in the paragraph *A method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque.*

35 *A method for diagnosing a mammal who has or may be at risk of developing atherosclerosis*

According to the invention, a method for diagnosing a mammal who has or is at risk of developing atherosclerosis is included. The method comprises the steps of

- a) determining the amount of integrin alpha10 chain in a mammal,

- b) scoring the amount of integrin alpha10 chain in said mammal, relative to a control, and
- c) correlating the amount obtained in step b) above to determine whether the mammal has or is at risk of developing atherosclerosis.

5 In further embodiments, the method is a quantitative method, wherein the amount of integrin alpha10 chain is determined relative to the control in a quantitative manner.

A protein, such as an antibody or a fragment thereof or a polypeptide, said protein binding specifically to the integrin alpha10 chain, unlabelled or labelled with 10 an agent such as biotin, a fluorescent probe or an isotope may be used. A polypeptide binding specifically to the integrin alpha10 chain may be e.g. parts of the antigen binding site of an antibody binding to the integrin alpha10 chain, or any other polypeptide with a binding affinity to the integrin alpha10 chain. Said protein will be detected either directly or used to direct a contrast agent, such as gadolinium 15 to the atherosclerotic plaque. Bound antibody or contrast agent may be visualized using techniques such as high-resolution magnetic resonance imaging (MRI), ultrasound, fluorescence emission spectroscopy or nuclear imaging. Any other suitable method known to the skilled man in the art may also be used. The amount of bound contrast agent, which can be quantified using techniques mentioned above, will, 20 thus, reflect the amount integrin alpha10 chain in the tissue (Naghavi M *et al.*. Current Atherosclerosis Reports 2001; 3:125-135. Yu X *et al.* Magnetic Resonance in Medicine 2000; 44:867-872. Flacke S *et al.* Circulation 2001; 104:1280-1285. Tsimikas S *et al.* Arterosler. Thromb. Vasc. Biol. 2000; 20:289-697).

In even further embodiments, the amount of the integrin alpha10 chain is 25 determined in a biopsy from the mammal, such as a mouse, rat or human.

Further embodiments include wherein the biopsy is from any blood vessel, such as an artery.

Even further embodiments include wherein determining of the amount of integrin alpha10 chain further comprises contacting atherosclerotic plaque, or part 30 of the mammal where the atherosclerotic plaque is suspected to be located, with a binding agent having a binding site specific for said integrin alpha10 chain. Said binding agent is further described in the paragraph *A method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque.*

Even further embodiments include wherein the scoring in b) above and 35 correlating in c) above is a scoring and correlation to a particular disease stage of atherosclerosis. Different ways of scoring atherosclerotic plaque are known and outlined in brief below.

The Committee on Vascular Lesions has attempted to correlate the appearance of lesions noted in clinical imaging studies with histological lesion types

and corresponding clinical syndromes. In the histological classification, lesions are designated by Roman numerals, which indicate the usual sequence of lesion progression as outlined in figure 1. The initial (type I) lesion contains enough atherogenic lipoprotein to elicit an increase in macrophages and formation of scattered macrophage foam cells. Type II lesions consist primarily of layers of macrophage foam cells and lipid-laden smooth muscle cells and include lesions grossly designated as fatty streaks. Type III is the intermediate stage between type II and type IV (*atheroma*, a lesion that is potentially symptom-producing). In addition to the lipid-laden cells of type II, type III lesions contain scattered collections of extracellular lipid droplets and particles that disrupt the coherence of some intimal smooth muscle cells. This extracellular lipid is the immediate precursor of the larger, confluent, and more disruptive core of extracellular lipid that characterizes type IV lesions. Beginning around the fourth decade of life, lesions that usually have a lipid core may also contain thick layers of fibrous connective tissue (type V lesion) and/or fissure, hematoma, and thrombus (type VI lesion). Some type V lesions are largely calcified (type Vb), and some consist mainly of fibrous connective tissue and little or no accumulated lipid or calcium (type Vc) (Stary HC *et al.* Circulation 1995; 92:1355-1374).

According to the criteria of the American Heart Association Committee on Vascular lesions, lesion progression can be divided into five phases as outlined in figure 1. The progression is based on pathological and clinical findings. In phase 1, early lesions are found (lesions type I-III). These lesions can then progress into phase 2 with fibrolipid plaques (lesions type IV-Va). Phase 2 can progress into an acute phase (phase 3 or 4) and phase 3 and 4 lesions are of type VI. Formation of thrombosis or hematoma may cause angina pectoris (phase 3) or acute coronary syndrome due to occlusive thrombosis (phase 4). Phase 3 and 4 lesions can evolve into a fibrotic phase (phase 5) characterized by more stenotic plaques (lesions type Vb-c) that may progress to occlusive lesions (Fayad ZA *et al.* Circ Res 2001; 98:305-316).

30

A method for detecting atherosclerotic plaque in a mammal

According to the invention a method for detecting atherosclerotic plaque in a mammal is disclosed. Such a method comprises the steps of

- a) determining the amount of integrin alpha10 chain in a mammal.
 - b) scoring the amount of integrin alpha10 chain in said mammal, relative to a control, and
 - c) correlating the amount obtained in step b) above with amounts obtained from a control to detect the amount of atherosclerotic plaques.
- In further embodiments, the method is a quantitative method, wherein the

amount of integrin alpha10 chain in a mammal is determined relative to the control sample in a quantitative manner.

In even further embodiments, the amount of the integrin alpha10 chain is determined in a biopsy from the mammal, such as a mouse, rat or human.

5 Further embodiments include wherein the biopsy is from any blood vessel, such as an artery.

Further embodiments include wherein the amount of integrin alpha10 chain is determined *in vivo*.

Further embodiments include wherein the amount of integrin alpha10 chain is 10 determined *in vitro* in a biopsy from said mammal, such as a mouse, rat or human.

Further embodiments include wherein the determining of the amount of integrin alpha10 chain is performed by immunohistochemical analysis *in vitro*. Such methods are known to the skilled man in the art, and further exemplified in the example below.

15 In brief, the tissues are fixed by fixative or frozen using methods known to the skilled man in the art. After the tissues are fixed, they may be embedded in paraffin or mounted in Tissue Tek® O.C.T. compound (Sakura Finetek Europe B.V., The Netherlands) and frozen for further sectioning. Paraffin-embedded tissues are cut using e.g. a microtome at room temperature, whereas frozen tissues are cut using 20 a cryostat at temperatures below 0°C. Sections are then treated in a way that best retrieve the antigen several methods are available and known to the skilled man in the art. Furthermore, the tissue sections may be blocked for any endogenous antigens or staining that can be detected by the detection system as background. The sections are then incubated with antibodies specific to integrin alpha10 chain. The 25 antibody may be labelled with agents such as fluorescence, enzyme or biotin that then are detected with suitable detection system. Alternatively, a secondary antibody, labelled with agents such as fluorescence, enzyme or biotin may be used to detect the anti-integrin alpha10 chain antibody. The amount of staining may be measured using computerized imaging systems. The amount of staining correlates to the amount of alpha 10 chain in the tissue. (Camper L et al Cell Tissue Res. 2001; 306:107-116)

30 Further embodiments include wherein the determining of the amount of integrin alpha10 chain is done by any invasive or non-invasive method *in vivo*, such as any imaging method. Examples of such methods are Magnetic Resonance Imaging (MRI), Ultrasound such as intravascular ultrasound (IVUS), Computed tomography, such as Electron Beam Computed Tomography (EBCT) and multislice tomographic scanning, as well as angiography. Any other suitable method known to the skilled man in the art may also be used.

Even further embodiments include wherein determining of the amount of

integron alpha10 chain further comprises contacting the sample with a binding agent having a binding site specific for said integrin alpha10 chain. Said binding agent is further described in the paragraph *A method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque.*

5

A method for modulating the expression of the integrin alpha10 chain.

The expression of the integrin alpha10 may also be modulated by gene targeting of the gene(s) encoding the alpha10 protein expression in a mammalian cell. The cell to be targeted may be targeted in vitro or in vivo in a mammal, such as 10 a human or a mouse. In vitro techniques for modulating expression of a specific gene, or group of genes are known to a person skilled in the art. Examples are given in Talts JF., Brakebusch C., Fassler, R (1999) Integrin gene targeting. Methods Mol. Biol 129, 153-187, Kozarsky KF (2001) Current Opinion in Pharmacology 1:1997-202).

15 In brief, a gene is normally targeted by a construct encoding a complementary nucleic acid sequence to the gene of interest to target. The whole gene may be targeted, as well as a part thereof. "A part thereof" here refers to a part of the gene that will regulate the expression directly or indirectly, such as the promotor or other regulatory sequences of the gene, as well as the intron or exon sequences of the 20 gene. Thus, the expression of the alpha10 protein may, due to the targeting at the gene level, be modulated to e.g. down-regulate or up-regulate the expression of the alpha10 integrin protein.

According to the invention, a method for modulating the expression of the integrin alpha10 chain in a cell in an atherosclerotic plaque is disclosed. Such a 25 method comprises the steps of:

- a) providing a construct targeting the integrin alpha10 chain gene, parts thereof or regulatory sequences to the gene,
- b) contacting the cell expressing the integrin in an atherosclerotic plaque in vivo or in vitro with said construct,
- c) transforming the cell in vivo or in vitro,
- d) optionally selecting the transformed cell in vivo or in vitro,
- e) detecting the protein expression of the alpha10 chain protein,
- f) correlating the protein expression of the alpha10 chain protein to the expression before providing the construct in a) above, thereby evaluating 30 the modulation of the expression of the integrin alpha10 chain protein.

35 Modulating the expression of the integrin alpha10 chain may be done directly or indirectly through other factors that control the integrin alpha10 protein expression. Examples of factors are growth factors such as fibroblast growth factor, insulin-like growth factor, transforming growth factor-beta, parathyroid hormone-

related peptide, bone morphogenic proteins, Indian hedgehog and sonic hedgehog; transcription factors such as SOX5-6 and SOX9 or other factors that modulates the expression of integrin alpha10 protein.

A construct may comprise any agent that targets the integrin alpha10 chain gene, parts thereof or regulatory sequences to the gene. It may also target genes, parts thereof or regulatory sequences to genes of factors that modulate the expression of the integrin alpha10 protein.

Furthermore, the construct may comprise a viral or non-viral system for the *in vivo* delivery of any of the genes, parts thereof or regulatory sequences to the genes described above. Examples of viral vectors include retroviruses, adenoviruses, adenoviruses, adeno-associated viruses (AAV), herpes simplex virus and lentivirus. Examples of non-viral delivery systems include the use of naked DNA, cationic liposomes, cationic lipids and polymers as well as DNA/cationic liposome/polycation complexes.

The expression of the exogenous genetic material *in vivo* is often referred to as "gene therapy". Disease states and procedures for which such treatments and methods according to the invention have application include genetic disorders and diseases of the vascular system such as atherosclerosis. Cell delivery of the transformed cells may be effected using various methods and includes infusion. One example of an infusion method is described by Tangirala RK et al. (1999) *Circulation* 100:1816-1822.

A construct may further include a chemical compound that targets the integrin alpha10 chain gene, parts thereof or regulatory sequences to the gene. It may also target genes, parts thereof or regulatory sequences to genes of factors that modulate the expression of the integrin alpha10 protein, as described above.

Anti-sense technique may be used to modulate the transcription of the genes, mentioned above, that in the end affects the expression of integrin alpha10 chain. The construct could include anti-sense DNA or RNA, i.e. DNA or RNA oligonucleotids that are complimentary to a given mRNA sequence of interest. The binding of the DNA and RNA oligonucleotids to the mRNA will block the translation of that particular mRNA.

Examples of delivery systems for anti-sense include the use of naked DNA or RNA, cationic liposomes, cationic lipids and polymers as well as DNA/cationic liposome/polycation complexes.

Furthermore, the construct may include a viral vector for the *in vivo* delivery of any of the genes, parts thereof or regulatory sequences to the genes described above. Examples of viral vectors include retroviruses, adenoviruses, adenoviruses, adeno-associated viruses (AAV), herpes simplex virus and lentivirus

Further embodiments include wherein the targeting of the gene is modulating

the expression so as to up-regulate the expression of the alpha10 chain protein. The up-regulation may, thus, be to a normal level of the gene. A "normal level" is herein intended to mean a level about what the cell in a specific mammal normally expresses in that particular cell type and activation stage of that cell type. This is 5 sometimes referred to as the wild type expression as well.

Even further embodiments include in vivo modulation of the integrin alpha10 chain protein expression. Such in vivo modulation may as well be due to a regulation at the gene level due to targeting of the gene in vivo. Thus, the expression of the alpha10 protein may, due to the targeting at the gene level, be modulated to 10 e.g. down regulate the expression of the protein in vivo.

Further embodiments include wherein the targeting of the gene is modulating the expression so as to up-regulate the expression of the aplha10 chain protein in vivo.

The method above may be used as a gene therapeutic method for modulating 15 the expression of the integrin alpha10 chain protein. Such a use may be to suppress, prevent, increase or decrease the in vivo expression in a mammal, such as a human, mouse or rat, in the need thereof. By re-introduction of nucleic acid, such as deoxynucleic acid (DNA), ribonucleic acid (RNA), peptide nucleic acid (PNA) or mixtures thereof, the activity may be modulated and e.g. an absence or over-expression of the integrin alpha10 chain protein partially or fully compensated. 20

Still another use of the method according to the invention is to prevent, inhibit, alleviate or reverse activity in atherosclerosis.

The mammal

25 For the methods and uses disclosed, a mammal is considered. In further embodiments, the mammal may be a human being.

Still further embodiments include wherein the mammal is a rodent, such as a rat or mouse or any other member of the family Muridae.

Further embodiments include wherein the mammal is a rabbit, or a primate, 30 such as chimpanzees, squirrel monkeys, howler monkeys, rhesus monkeys and cynomolgus monkeys, or a pig, e.g. the White Belgian pig.

Further embodiments include wherein the mammal is fed a high-cholesterol and/or high-fat diet.

In some of the methods and uses, a mammal in the need there of is disclosed. 35 Such a mammal, e.g. a human or mouse, may be any mammal showing early signs of atherosclerotic plaque, fully developed atherosclerotic plaque, or being predisposed to or in the risk of forming an atherosclerotic plaque.

Different conditions may lead to atherosclerosis in a mammal. Thus, further embodiment include wherein the atherosclerosis in a mammal is caused by

conditions such as type 1 diabetes, ApoA1 deficiency, a cardiovascular disorder, e.g. coronary artery disease (CAD), systemic lupus erythematosis (SLE), acute ischemia, chronic ischemia or Sjögren's syndrome.

Other risk factors for atherosclerosis include hypertension, elevated levels of
5 low density lipoprotein, reduced levels of high density lipoprotein, cigarette smoking, diabetes mellitus, obesity, male sex, elevated homocysteine levels, chlamydia pneumoniae infection, and family history of premature atherosclerosis. Thus, even further embodiments include wherein the mammal in the need thereof is
10 a mammal being exposed to different risk factors involved in atherosclerosis, such as the risk factors mentioned above.

Uses according to the invention

According to the invention, several uses of the integrin alpha10 chain are disclosed.

15 A use of the integrin alpha10 chain for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque is included.

Further, a use of the integrin alpha10 chain for the preparation of a composition for the treatment of atherosclerosis is included. Such a treatment of atherosclerosis is for a mammal in the need thereof. The mammal, e.g. a human or
20 mouse, may be any mammal showing early signs of atherosclerotic plaque, fully developed atherosclerotic plaque, or being predisposed to or in the risk of forming an atherosclerotic plaque.

Further, a use of integrin alpha10 chain for diagnosing atherosclerosis is disclosed.

25 Even further, a use of integrin alpha10 chain for detecting atherosclerotic plaque is included.

EXAMPLES

30 Example 1 Detection of the integrin alpha10 chain in aortic atherosclerotic plaque

Objective

The objective of this example is to describe detection of the integrin alpha10 chain in aortic atherosclerotic plaque.

35

Material

Murine aortic plaque sections were used. The sections were cut on a cryostat at a thickness of 5µm onto Superfrost Plus slides (Menzel-Gläser, Histolab). The cut sections were then stored at -20°C.

Detection of the aortic plaques

Before staining, the frozen sections were allowed to thaw to room temperature for about 30 minutes.

5 The sections were fixed in acetone for 10 minutes at -20°C, and then treated with hyaluronidase (2mg/ml, Sigma) for 30 minutes at 37°C.

The sections were blocked with 4% donkey serum (Harlan) diluted in PBS for 30 minutes at room temperature.

10 During the blocking step, an anti-alpha10 antibody was incubated with an alpha10 peptide, i.e. the blocking peptide, at different concentrations, e.g. 0.01, 0.1, and 0.5 mg/ml, for 30 minutes at 4°C.

15 The sections were then incubated with rabbit anti-human alpha10, in 1:100 dilution, and a fraction of the preincubated rabbit anti-human alpha10 and the blocking peptide in a 1:100 dilution. The sections were incubated for 75 minutes at room temperature.

After a 15-minute wash in PBS, the sections were incubated with donkey anti-rabbit Cy3 (IgG, 1:100, from Jackson) for 60 minutes in room temperature.

After a final 15-minute wash in PBS, the sections were mounted with Vectashield (Vector Labs), and photographed under a fluorescent microscope.

20

Results and discussion

In figure 2, the result of the staining to detect the integrin alpha10 expression in the aortic plaques is shown. The top picture, A, shows the staining of the integrin alpha10 chain as a strong staining around the outside of the cells in the aortic 25 plaque. The middle photo, B, shows a specific blocking of the integrin alpha10 chain staining with a peptide of the integrin alpha10 chain, wherein almost all staining has been blocked by the peptide. The bottom photo, C, shows a control staining with the secondary antibody used. No unspecific binding due to the staining with the secondary antibody, a donkey-anti-rabbit Cy3, is detected.

30

Example 2 Evaluating the involvement of integrin alpha10 chain in neointima formation following vascular injury in integrin alpha10 chain deficient mice*Objective*

35 The objective of this example is to evaluate the role and function of integrin alpha10 chain in the formation of neointima (or atherosclerotic plaque) and cholesterol levels following vascular injury.

Animals

Integrin chain alpha $10^{-/-}$ mice and wild-type age and gender matched control mice.

5 Mouse artery injury

Several methods for mechanically induced artery injury on mice are available and known to the skilled man in the art. One example, carotid cuff-injury, is presented here (Dimayuga P *et al*, Biochemical and Biophysical Research Communications, 1999; 264:465-468).

10 The animals are anesthetized with isoflurane followed by Avertin (intraperitoneal injection of 0.016 ml/g bodyweight of a 2.5% solution).

The right carotid artery is carefully isolated under a dissection microscope.

A 2.5 mm long tube is applied around the carotid artery and the skin incision is closed.

15

Analysis

The size of the neointima will be measured and its content with respect to cells such as inflammatory cells, smooth muscle cells, fibroblasts and endothelial cells and extracellular matrix components such as collagens, proteoglycans and 20 fibronectin and different cell surface markers such as integrins will be analysed using different staining techniques and specific antibodies known to the skilled man in the art.

Mice are killed 3 weeks after the induced injury.

25 The carotid arteries are carefully dissected out and perfused with 0.9% saline, embedded in Tissue Tek® O.C.T. compound (Sakura Finetek Europe B.V., The Netherlands) and frozen in -70°C or alternatively fixated in phosphate-buffered formalin and embedded in paraffin.

30 Sections of the tissue are then stained with hematoxylin and eosin staining and /or Verhoeff Van-Gieson staining for morphological studies. Morphometric analyses will be performed with Verhoeff Van-Gieson-stained sections.

Measurements of luminal area, area inside the internal elastic lamina (IELA), and the area encircled by external elastic lamina will be made on each section.

35 Medial area will be calculated by subtracting IELA from external elastic lamina, and intimal area (IA) will be calculated by subtracting luminal area from IELA. From these measurements, the ratio of IA and medial area (I/M ratio) will be calculated. Computer assisted image analysis will be used for quantitative assessment of stainings and for morphometric analyses of the neointima (systems such as Optimas System, Bioscan or Scion Image analysis software, Scion) (Dimayuga P *et al*,

Biochemical and Biophysical Research Communications, 1999; 264:465-468, Zhu *et al*, Arterioscler Thromb Vasc Biol 2002; 22:450-455).

Plasma samples will be collected for measurements of total cholesterol levels using an enzymatic assay (Sigma, St Louis, MO, U.S.A.) HDL levels will be
5 measured after precipitating apo-B containing lipoproteins with phosphotungstic acid (Sigma, St Louis, MO, U.S.A.).

Also levels of tissue cholesterol will be measured as described in (Dimayuga P *et al*, Biochemical and Biophysical Research Communications, 1999; 264:465-468).

10

Example 3 Evaluating the involvement and function of integrin alpha10 chain in development atherosclerosis in integrin chain alpha 10^{-/-} apoE^{-/-} mice

Objective

15 The objective with this example is to create a double knock-out mouse, deficient for both the integrin alpha10 chain and apoE (alpha10^{-/-} apoE^{-/-}).

One further objective is to compare the alpha10^{-/-} apoE^{-/-} with age and gender matched single knock-out mice (alpha10^{-/-} and apoE^{-/-}) and wild-type control mice with respect to the development of atherosclerosis and cholesterol levels.

20

Animals

Integrin chain alpha10^{-/-}, apoE^{-/-} mice and age and gender matched wild-type controls. The mice will be fed standard chow diet (such as PicoLab Rodent chow 20, 4,5% fat by weight, 0,02% cholesterol) or Western-type diet (such as Tekland 25 Adjusted Calories Western-type diet, 21% fat by weight, 0,15% cholesterol, 19,5% casein without sodium cholate).

Generation of alpha10^{-/-} apoE^{-/-} double knock-out mice

30 Homozygous integrin chain alpha 10^{-/-} mice will be mated with homozygous apoE^{-/-} mice. The generated heterozygous F1 mice will further be used to generate mice homozygous for both alpha10 and apoE deficiency.

Analysis of atherosclerosis development in the integrin chain alpha10^{-/-} and apoE^{-/-} double knock-out mice

35 The size of the neointima will be measured and its' content with respect to cells such as inflammatory cells, smooth muscle cells, fibroblasts and endothelial cells and extracellular matrix components such as collagens, proteoglycans and fibronectin and different cell surface markers such as integrins will be analysed

using different staining techniques and specific antibodies known to the skilled man in the art.

Mice will be killed at different ages to investigate the progression of the atherosclerosis.

5 The arteries are carefully dissected out and perfused with 0.9% saline, embedded in Tissue Tek® O.C.T. compound (Sakura Finetek Europe B.V., The Netherlands) and frozen in -70°C or alternatively fixated in phosphate-buffered formalin and embedded in paraffin.

10 Sections of the tissue are then stained with hematoxylin and eosin staining and /or Verhoeff Van-Gieson staining for morphological studies.

Morphometric analyses will be performed with Verhoeff Van-Gieson-stained sections.

Measurements of luminal area, area inside the internal elastic lamina (IELA), and the area encircled by external elastic lamina will be made on each section.

15 Medial area will be calculated by subtracting IELA from external elastic lamina, and intimal area (IA) will be calculated by subtracting luminal area from IELA. From these measurements, the ratio of IA and medial area (I/M ratio) will be calculated. Computer assisted image analysis will be used for quantitative assessment of stainings and for morphometric analyses of the neointima (systems such as Optimas System, Bioscan or Scion Image analysis software, Scion) (Dimayuga P *et al*, Biochemical and Biophysical Research Communications, 1999; 264:465-468, Zhu *et al*, Arterioscler Thromb Vasc Biol 2002; 22:450-455).

20 Plasma samples will be collected for measurements of total cholesterol levels using an enzymatic assay (Sigma, St Louis, MO, U.S.A.) HDL levels will be measured after precipitating apo-B containing lipoproteins with phosphotungstic acid (Sigma, St Louis, MO, U.S.A.).

25 Also levels of tissue cholesterol will be measured as described in (Dimayuga P *et al*, Biochemical and Biophysical Research Communications, 1999; 264:465-468).

30 Results from the integrin chain alpha 10^{-/-}, apoE^{-/-} double knock-out mice will be compared with age and gender matched single knock-out mice (integrin chain alpha 10^{-/-} and apoE^{-/-} knock-out mice) and wild-type control mice.

CLAIMS

1. A method for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque in a mammal, the method comprising the steps of
 - 5 a) administering to the mammal an effective amount of a binding agent having a binding site specific for integrin alpha10 chain or nucleic acid encoding said chain on the cell surface or intracellular of said mammal,
 - b) scoring the progression and/or regression of atherosclerotic plaque, and
 - c) correlating the scoring in b) above to slowing or arresting the progression
- 10 and/or effecting the regression of said atherosclerotic plaque.
2. The method according to claim 1, wherein the cell surface is the cell surface of a smooth muscle cells.
- 15 3. The method according to claim 1, wherein the binding agent has a binding site intracellular of a smooth muscle cells.
4. A method for treating atherosclerosis in mammals in the need thereof, the method comprising the step of administering to the mammal an effective amount
 - 20 of a binding agent having a binding site specific for integrin alpha10 chain on the cell surface or intracellular of said mammal.
5. A method for diagnosing a mammal who has or may be at risk of developing atherosclerosis, the method comprising the steps of
 - 25 a) determining the amount of integrin alpha10 chain in a mammal.
 - b) scoring the amount of integrin alpha10 chain in said mammal, relative to a control,
 - c) correlating the amount obtained in step b) above with amounts obtained from the control to determine whether the mammal has or is at risk of developing atherosclerosis.
- 30 6. The method according to claim 5, wherein the determining is performed in vivo.
7. The method according to claim 5, wherein the determining is performed in vitro.
- 35 8. The method according to any of claims 5-7, wherein determining of the amount of integrin alpha10 chain further comprises contacting the integrin alpha10 chain with a binding agent having a binding site specific for said of integrin alpha10 chain.

9. A method for detecting atherosclerotic plaque in a mammal, the method comprising the steps of
 - a) determining the amount of integrin alpha10 chain in a mammal,
 - 5 b) scoring the amount of integrin alpha10 chain in said mammal, relative to to a control, and
 - c) correlating the amount obtained in step b) above with amounts obtained from the control to detect said atherosclerotic plaque in the mammal.
- 10 10. The method according to claim 9, wherein the determining is performed in vivo.
11. The method according to claim 9, wherein the determining is performed in vitro.
12. The method according to any of claims 9-11, wherein determining of the amount 15 of integrin alpha10 chain further comprises contacting integrin alpha10 chain with a binding agent having a binding site specific for said of integrin alpha10 chain.
13. The methods according to any of claims 1-12, wherein the mammal is a human.
- 20 14. The methods according to any of claims 1-12, wherein the mammal is a mouse.
15. Use of integrin alpha10 chain for slowing or arresting the progression and/or effecting regression of atherosclerotic plaque.
- 25 16. Use of integrin alpha10 chain for the preparation of a composition for the treatment of atherosclerosis.
17. Use of integrin alpha10 chain for diagnosing atherosclerosis.
- 30 18. Use of integrin alpha10 chain for detecting atherosclerotic plaque.




Figure 1/2




A**alpha-10****B****alpha-10 + peptide****C****control**

Figure 2

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.